Alembic Pharmaceuticals surged 10.92% to Rs 1,078 after the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...

Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered ...

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

The company received USFDA approval for Doxorubicin Hydrochloride Injection, which will be use for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma, and Multiple Myeloma.

Alembic Pharmaceuticals share surged after the company received final approval from the USFDA for its ANDA for Doxorubicin Hydrochloride Liposome Injection in two dosage strength.

Alembic Pharmaceuticals shares surged over 12 per cent after receiving USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injection, used to treat ovarian cancer, Kaposi Sarcoma, and ...

The buyer in this case is Alembic’s US subsidiary, Alembic Pharmaceuticals Inc., which will take over full ownership of Utility.

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...

Vadodara: Alembic Pharma has appointed G Krishnan as the Chief Financial Officer (CFO) and Key Managerial Personnel of the ...

According to IQVIA, the market for Doxorubicin Hydrochloride Liposome Injection is estimated at $29 million for the twelve months ending March 2025.

The shares of this leading pharmaceutical company are in focus after the company secured the USFDA's approval for its key ...

Vadodara: Alembic Pharmaceuticals Inc., a wholly owned subsidiary of Alembic Pharmaceuticals Limited, has acquired a 100 ...